2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
10.12997/jla.2022.11.3.213
- Author:
Chan Joo LEE
1
;
Minjae YOON
;
Hyun-Jae KANG
;
Byung Jin KIM
;
Sung Hee CHOI
;
In-Kyung JEONG
;
Sang-Hak LEE
;
On behalf of Task Force Team for Familial Hypercholesterolemia, Korean Society of Lipid and Atherosc
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Publication Type:Review
- From:Journal of Lipid and Atherosclerosis
2022;11(3):213-228
- CountryRepublic of Korea
- Language:English
-
Abstract:
Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein-cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and <70 mg/dL or <55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C >500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.
